rSIFN-co
Phase 2Biologic
rSIFN-co is one of 21 biologic programs targeting COVID-19. It is currently in Phase 2.
2
Indications
4
Total Trials
1
Active Trials
20
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1931 competitors in COVID-19
#DrugCompanyPhaseTrials
1Singulair
AstraZenecaPreclinical
Nexavar
BayerPreclinical
Activella
Eli LillyPreclinical
rSIFN-co
SSichuan Huiyang Life Science and Technology Corporation
Phase 2
Proventil
Mylan Pharmaceuticals IncPreclinical
Rayaldee
OOrganon and Co
Preclinical
SARS-COV-2 VACCINE
ModernaPreclinical
Achromycin V
WWyeth-Lederle Vaccines
Preclinical
Statins
SanofiPreclinical
Antihypertensive Agents
NNational Heart, Lung, and Blood Institute (NHLBI)
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Locally-advanced Rectal Cancer1 trial
A Randomized, Multi-Center, Open-Label, Phase II Study to Evaluate the Efficacy and Safety of Recombinant Super-Compound Interferon (rSIFN-co) in Combination With Total Neo-adjuvant Therapy, in Subjects With Mid-low Locally Advanced Rectal Cancer
Not yet recruiting·SSichuan Huiyang Life Science and Technology Corporation·Phase 2·NCT07662278·90 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for rSIFN-co. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details